免疫腫瘤診斷藥的全球市場 - 附執行/顧問指南與客制化預測/分析(2025年～2029年) - 人工智能的影響

診斷和伴隨診斷正在推動免疫腫瘤治療的成功。診斷產業正在催生一個全新的細分市場，而且規模龐大，有望實現指數級成長。組織學、基因組學和液體活檢正在融合。由製藥公司、診斷公司和設備供應商組成的複雜網路正在競相探索新的抗癌方法。這些方法似乎正在發揮作用，並展現出巨大的潛力。

癌症治療領域正在進行一場革命。利用人體天然免疫防禦機制的新療法取得了前所未有的成功。然而，人們迫切需要診斷方法，尤其是生物標記，以便選擇正確的治療方法。

技術進步的速度快於市場發展的速度。這對醫療保健產業的影響是巨大的。我們為您揭秘諸如腫瘤突變負荷、檢查點抑制劑和細胞激素等專業術語。

本報告提供全球免疫腫瘤診斷藥市場相關調查，市場概要，以及各用途，各技術，各用戶趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 市場指南

• 情形分析
• 高階主管和行銷人員指南
• 投資分析師和經營顧問的指南
• 人工智能的影響

第2章 簡介和市場定義

• 免疫腫瘤診斷藥是什麼嗎
• 免疫腫瘤學- 迫近來的治療方法
• 市場定義
• 調查手法
• 觀點:醫療保健和IVD產業

第3章 免疫療法- 免疫技術指南

• 免疫系統
  • 先天性免疫系統
  • 適應免疫系統
  • 腫瘤免疫學- 免疫監測系統
• 免疫腫瘤診斷藥
  • 查核點化驗
  • 細胞激素化驗
  • 基因生殖細胞系列
  • 基因腫瘤
  • 腫瘤微環境
  • 其他

第4章 產業概要

• 市場進入組織
  • 學術研究機關
  • 診斷測試開發商
  • 測量設備供應商
  • 藥品·試劑廠商
  • 病理供應商
  • 獨立型臨床檢驗室
  • 公共的國立/地區研究所
  • 醫院檢驗室
  • 臨床檢驗室
  • 審核機關
  • 認證機關

第5章 市場趨勢

• 成長促進因素
• 阻礙成長的要素
• 診斷技術開發

第6章 癌症免疫腫瘤診斷藥的最近的趨勢

第7章 主要免疫腫瘤學企業的簡介

• 10x Genomics, Inc.
• Abbott Laboratories
• AccuraGen Inc.
• Adaptive Biotechnologies
• Aethlon Medical
• Agilent
• Anchor Dx
• ANGLE plc
• ARUP Laboratories
• AVIVA Systems Biology
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics(Danaher)
• Becton, Dickinson and Company
• Berkley Lights
• BGI Genomics Co. Ltd
• Bioarray Genetics
• Biocartis
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• BioGenex
• BioIVT
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc.
• Bio-Reference Laboratories
• Bio-Techne
• Bioview
• Bristol-Myers Squibb
• Burning Rock
• Cardiff Oncology
• Caris Molecular Diagnostics
• Castle Biosciences, Inc.
• CellCarta
• CellMax Life
• Cepheid(Danaher)
• Charles River Laboratories
• Circulogene
• Cizzle Biotech
• Clearbridge Biomedics
• Clinical Genomics
• Cytolumina Technologies Corp.
• Datar Cancer Genetics Limited
• Diagnologix LLC
• Diasorin S.p.A.
• Dxcover
• Element Biosciences
• Enzo Biochem
• Epic Sciences
• Epigenomics AG
• Eurofins Scientific
• Fabric Genomics
• Fluxion Biosciences(Cell Microsystems)
• Freenome
• FUJIFILM Wako Diagnostics
• Fujirebio
• Fyr Diagnostics
• GeneFirst Ltd.
• Genetron Holdings
• GenomOncology
• GILUPI Nanomedizin
• Guardant Health
• HansaBiomed
• HTG Molecular Diagnostics
• iCellate
• ICON PLC
• Illumina
• Incell Dx
• Inivata
• INOVIQ
• Invitae Corporation
• Invivogen
• Invivoscribe
• J&J Innovative Medicine
• KEW
• Lucence Health
• Lunglife AI Inc
• MDNA Life SCIENCES, Inc.
• MDx Health
• Menarini Silicon Biosystems
• Mesa Laboratories, Inc.
• Millipore Sigma
• Miltenyi Biotec
• miR Scientific
• Myriad Genetics
• Nanostring
• NantHealth, Inc.
• Natera
• NeoGenomics
• NGeneBio
• Novogene
• Oncimmune
• Oncocyte
• OncoDNA
• Oncohost
• Oxford Nanopore Technologies
• PamGene
• Panagene
• Personalis
• PGDx(Labcorp)
• Precipio
• PrecisionMed
• Predicine
• Predictive Oncology
• Prenetics
• Promega
• Qiagen
• QuidelOrtho
• Rarecells SAS
• RareCyte
• Recursion Pharma
• Revvity
• Roche Diagnostics
• Screencell
• Sherlock Biosciences
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singular Genomics
• Singulomics
• SkylineDx
• Standard BioTools
• Stilla Technologies
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific
• Todos Medical
• Ultima Genomics
• Veracyte
• VolitionRX
• Vortex Biosciences

第8章 全球腫瘤免疫診斷藥市場

• 各國全球市場概要
• 各化驗類型全球市場- 概要
• 各技術全球市場- 概要
• 各用戶全球市場- 概要

第9章 全球免疫腫瘤診斷藥市場- 各用途

• 查核點
• 細胞激素
• 生殖細胞遺傳學
• 遺傳性腫瘤
• 腫瘤微環境
• 其他

第10章 全球免疫腫瘤診斷藥市場- 各技術

• NGS
• PCR
• FISH/IHC
• 化學/IA
• 其他

第11章 全球免疫腫瘤診斷藥市場- 各用戶

• 製藥
• 診所
• 其他

第12章 附錄

OVERVIEW:

Diagnostics, companion diagnostics, is driving the success of Immuno-oncology Therapeutics. An entire new segment of the diagnostics industry is being created. And its not a small segment either. It promises to grow dramatically. Histology, genomics and liquid biopsy are converging. A complicated network of pharmaceutical companies, diagnostic companies and instrumentation suppliers are jockeying for position in a new approach to conquering cancer. The approach seems to be working and showing great promise.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size in this new expanded and comprehensive report.

Table of Contents

1. Market Guides

• 1.1. Situation Analysis
• 1.2. Guide for Executives and Marketing Staff
• 1.3. Guide for Investment Analysts and Management Consultants
• 1.4. Impact of Artificial Intelligence

2. Introduction and Market Definition

• 2.1. What are Immuno-Oncology Diagnostics?
• 2.2. Immuno-oncology - the looming cure
  • 2.2.1. Immuno-oncology Diagnostics Takes a Leading Role
• 2.3. Market Definition
  • 2.3.1. Market Size
  • 2.3.2. Currency
  • 2.3.3. Years
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare and the IVD Industry
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Diagnostics
  • 2.5.3. Important Role of Insurance for Diagnostics

3. Immunotherapy - Guide to Immune Technologies

• 3.1. The Immune System
  • 3.1.1. Innate immune system
    • 3.1.1.1. Surface barriers
    • 3.1.1.2. Inflammation
    • 3.1.1.3. Complement system
    • 3.1.1.4. Cellular barriers
    • 3.1.1.5. Natural killer cells
  • 3.1.2. Adaptive immune system
    • 3.1.2.1. Lymphocytes
    • 3.1.2.2. Killer T cells
    • 3.1.2.3. Helper T cells
    • 3.1.2.4. Gamma delta T cells
    • 3.1.2.5. B lymphocytes and antibodies
  • 3.1.3. Tumor immunology - the immune surveillance system
• 3.2. Immuno Oncology Diagnostics
  • 3.2.1. Checkpoint Assays
    • 3.2.1.1. Outlook for Checkpoint Assays
  • 3.2.2. Cytokine Assays
    • 3.2.2.1. Outlook for Cytokine Assays
  • 3.2.3. Genomic Germline
    • 3.2.3.1. Outlook for Genomic Germline
  • 3.2.4. Genomic Tumour
    • 3.2.4.1. Outlook for Genomic Tumour
  • 3.2.5. Tumor Microenviroment
    • 3.2.5.1. Outlook for Tumor Microenvironment
  • 3.2.6. Others
    • 3.2.6.1. Outlook for Other Diagnostics

4. Industry Overview

• 4.1. Players in a Dynamic Market
  • 4.1.1. Academic Research Lab
  • 4.1.2. Diagnostic Test Developer
  • 4.1.3. Instrumentation Supplier
  • 4.1.4. Chemical/Reagent Supplier
  • 4.1.5. Pathology Supplier
  • 4.1.6. Independent Clinical Laboratory
  • 4.1.7. Public National/regional Laboratory
  • 4.1.8. Hospital Laboratory
  • 4.1.9. Physicians Office Lab (POLS)
  • 4.1.10. Audit Body
  • 4.1.11. Certification Body

5. Market Trends

• 5.1. Factors Driving Growth
  • 5.1.1. Outcome potential
  • 5.1.2. Companion Diagnostics
  • 5.1.3. Funding
  • 5.1.4. Technology Environment
  • 5.1.5. Target Solutions
• 5.2. Factors Limiting Growth
  • 5.2.1. Complex Role of Diagnostics
  • 5.2.2. Clinical Trials Role
  • 5.2.3. Protocols
• 5.3. Diagnostic Technology Development
  • 5.3.1. Combinations - Issues and Complexity
  • 5.3.2. Shifting Role of Diagnostics
  • 5.3.3. Multiplexing and Foundation One
  • 5.3.4. The Disruption Dynamic
  • 5.3.5. The Race for Biomarkers
  • 5.3.6. The Next Five Years

6. Cancer Immuno-Oncology Diagnostics Recent Developments

• 6.1. Recent Developments - Importance and How to Use This Section
  • 6.1.1. Importance of These Developments
  • 6.1.2. How to Use This Section
• 6.2. Personalis Outlook Positive
• 6.3. Agilent Technologies Expands Certification for PD-L1 CDx
• 6.4. Foundation Medicine, Sumitomo Pharma to Develop CDx
• 6.5. Erisyon to Develop Diagnostic for Immuno-Oncology
• 6.6. Caris Life Sciences Expands CDx
• 6.7. FDA approves Illumina cancer biomarker test
• 6.8. Tempus Expands Immuno-Oncology Portfolio with AI
• 6.9. Foundation Medicine, Repare to Partner on CDx for Lunresertib
• 6.10. Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
• 6.11. ClearNote Health Expands Into Immunotherapy Monitoring
• 6.12. Foundation Medicine to Collaborate on CDx for Lung Cancer
• 6.13. Qiagen and Myriad Genetics Partner to Develop Cancer CDx
• 6.14. Lung Cancer Data Heralds Shift for Hummingbird Dx
• 6.15. PamGene Awarded Euro-7.5M for Immunotherapy Test
• 6.16. Freenome Acquires Oncimmune
• 6.17. Guardant Health Gets Coverage for Liquid Biopsy Treatment Response Test
• 6.18. BostonGene to Develop Sarcoma-Specific Liquid Biopsy
• 6.19. Exact Sciences OncoExTra Therapy Selection Test
• 6.20. Integrated DNA Technologies Buys NGS Research Assays
• 6.21. Navignostics Using Single-Cell Spatial Proteomics
• 6.22. New Reference Samples for NGS-Based Cancer Tests
• 6.23. Spatial Proteomics Panel for Immuno-Oncology
• 6.24. dMMR, MSI Assays for Immunotherapy Patient Selection
• 6.25. OncoHost Expands Prophet Platform Research
• 6.26. Protein-Based Liquid Biopsy Panel Assesses TME

7. Profiles of Key Immuno-oncology Companies

• 7.1. 10x Genomics, Inc.
• 7.2. Abbott Laboratories
• 7.3. AccuraGen Inc.
• 7.4. Adaptive Biotechnologies
• 7.5. Aethlon Medical
• 7.6. Agilent
• 7.7. Anchor Dx
• 7.8. ANGLE plc
• 7.9. ARUP Laboratories
• 7.10. AVIVA Systems Biology
• 7.11. Baylor Miraca Genetics Laboratories
• 7.12. Beckman Coulter Diagnostics (Danaher)
• 7.13. Becton, Dickinson and Company
• 7.14. Berkley Lights
• 7.15. BGI Genomics Co. Ltd
• 7.16. Bioarray Genetics
• 7.17. Biocartis
• 7.18. Biocept, Inc.
• 7.19. Biodesix Inc.
• 7.20. BioFluidica
• 7.21. BioGenex
• 7.22. BioIVT
• 7.23. Biolidics Ltd
• 7.24. bioMerieux Diagnostics
• 7.25. Bioneer Corporation
• 7.26. Bio-Rad Laboratories, Inc.
• 7.27. Bio-Reference Laboratories
• 7.28. Bio-Techne
• 7.29. Bioview
• 7.30. Bristol-Myers Squibb
• 7.31. Burning Rock
• 7.32. Cardiff Oncology
• 7.33. Caris Molecular Diagnostics
• 7.34. Castle Biosciences, Inc.
• 7.35. CellCarta
• 7.36. CellMax Life
• 7.37. Cepheid (Danaher)
• 7.38. Charles River Laboratories
• 7.39. Circulogene
• 7.40. Cizzle Biotech
• 7.41. Clearbridge Biomedics
• 7.42. Clinical Genomics
• 7.43. Cytolumina Technologies Corp.
• 7.44. Datar Cancer Genetics Limited
• 7.45. Diagnologix LLC
• 7.46. Diasorin S.p.A.
• 7.47. Dxcover
• 7.48. Element Biosciences
• 7.49. Enzo Biochem
• 7.50. Epic Sciences
• 7.51. Epigenomics AG
• 7.52. Eurofins Scientific
• 7.53. Fabric Genomics
• 7.54. Fluxion Biosciences (Cell Microsystems)
• 7.55. Freenome
• 7.56. FUJIFILM Wako Diagnostics
• 7.57. Fujirebio
• 7.58. Fyr Diagnostics
• 7.59. GeneFirst Ltd.
• 7.60. Genetron Holdings
• 7.61. GenomOncology
• 7.62. GILUPI Nanomedizin
• 7.63. Guardant Health
• 7.64. HansaBiomed
• 7.65. HTG Molecular Diagnostics
• 7.66. iCellate
• 7.67. ICON PLC
• 7.68. Illumina
• 7.69. Incell Dx
• 7.70. Inivata
• 7.71. INOVIQ
• 7.72. Invitae Corporation
• 7.73. Invivogen
• 7.74. Invivoscribe
• 7.75. J&J Innovative Medicine
• 7.76. KEW
• 7.77. Lucence Health
• 7.78. Lunglife AI Inc
• 7.79. MDNA Life SCIENCES, Inc.
• 7.80. MDx Health
• 7.81. Menarini Silicon Biosystems
• 7.82. Mesa Laboratories, Inc.
• 7.83. Millipore Sigma
• 7.84. Miltenyi Biotec
• 7.85. miR Scientific
• 7.86. Myriad Genetics
• 7.87. Nanostring
• 7.88. NantHealth, Inc.
• 7.89. Natera
• 7.90. NeoGenomics
• 7.91. NGeneBio
• 7.92. Novogene
• 7.93. Oncimmune
• 7.94. Oncocyte
• 7.95. OncoDNA
• 7.96. Oncohost
• 7.97. Oxford Nanopore Technologies
• 7.98. PamGene
• 7.99. Panagene
• 7.100. Personalis
• 7.101. PGDx (Labcorp)
• 7.102. Precipio
• 7.103. PrecisionMed
• 7.104. Predicine
• 7.105. Predictive Oncology
• 7.106. Prenetics
• 7.107. Promega
• 7.108. Qiagen
• 7.109. QuidelOrtho
• 7.110. Rarecells SAS
• 7.111. RareCyte
• 7.112. Recursion Pharma
• 7.113. Revvity
• 7.114. Roche Diagnostics
• 7.115. Screencell
• 7.116. Sherlock Biosciences
• 7.117. Siemens Healthineers
• 7.118. simfo GmbH
• 7.119. Singlera Genomics Inc.
• 7.120. Singular Genomics
• 7.121. Singulomics
• 7.122. SkylineDx
• 7.123. Standard BioTools
• 7.124. Stilla Technologies
• 7.125. Sysmex Inostics
• 7.126. Tempus Labs, Inc.
• 7.127. Thermo Fisher Scientific
• 7.128. Todos Medical
• 7.129. Ultima Genomics
• 7.130. Veracyte
• 7.131. VolitionRX
• 7.132. Vortex Biosciences

8. The Global Market for Immuno-Oncology Diagnostics

• 8.1. Global Market Overview by Country
  • 8.1.1. Table - Global Market by Country
  • 8.1.2. Chart - Global Market by Country
• 8.2. Global Market by Assay Type - Overview
  • 8.2.1. Table - Global Market by Assay Type
  • 8.2.2. Chart - Global Market by Assay Type - Base/Final Year Comparison
  • 8.2.3. Chart - Global Market by Assay Type - Base Year
  • 8.2.4. Chart - Global Market by Assay Type - End Year
  • 8.2.5. Chart - Global Market by Assay Type - Share by Year
  • 8.2.6. Chart - Global Market by Assay Type - Segments Growth
• 8.3. Global Market by Technology - Overview
  • 8.3.1. Table - Global Market by Technology
  • 8.3.2. Chart - Global Market by Technology - Base/Final Year Comparison
  • 8.3.3. Chart - Global Market by Technology - Base Year
  • 8.3.4. Chart - Global Market by Technology - End Year
  • 8.3.5. Chart - Global Market by Technology - Share by Year
  • 8.3.6. Chart - Global Market by Technology - Segments Growth
• 8.4. Global Market by Customer - Overview
  • 8.4.1. Table - Global Market by Customer
  • 8.4.2. Chart - Global Market by Customer - Base/Final Year Comparison
  • 8.4.3. Chart - Global Market by Customer - Base Year
  • 8.4.4. Chart - Global Market by Customer - End Year
  • 8.4.5. Chart - Global Market by Customer - Share by Year
  • 8.4.6. Chart - Global Market by Customer - Segments Growth

9. Global Immuno-Oncology Diagnostic Markets - By Application

• 9.1. Checkpoint
  • 9.1.1. Table Checkpoint - by Country
  • 9.1.2. Chart - Checkpoint Growth
• 9.2. Cytokine
  • 9.2.1. Table Cytokine - by Country
  • 9.2.2. Chart - Cytokine Growth
• 9.3. Germline Genetic
  • 9.3.1. Table Germline Genetic - by Country
  • 9.3.2. Chart - Germline Genetic Growth
• 9.4. Genetic Tumor
  • 9.4.1. Table Genetic Tumor - by Country
  • 9.4.2. Chart - Genetic Tumor Growth
• 9.5. Tumor Microenvironment
  • 9.5.1. Table Tumor Microenvironment - by Country
  • 9.5.2. Chart - Tumor Microenvironment Growth
• 9.6. Other
  • 9.6.1. Table Other - by Country
  • 9.6.2. Chart - Other Growth

10. Global Immuno-Oncology Diagnostic Markets - By Technology

• 10.1. NGS
  • 10.1.1. Table NGS - by Country
  • 10.1.2. Chart - NGS Growth
• 10.2. PCR
  • 10.2.1. Table PCR - by Country
  • 10.2.2. Chart - PCR Growth
• 10.3. Fish/IHC
  • 10.3.1. Table Fish/IHC - by Country
  • 10.3.2. Chart - Fish/IHC Growth
• 10.4. Chem/IA
  • 10.4.1. Table Chem/IA - by Country
  • 10.4.2. Chart - Chem/IA Growth
• 10.5. Other Technology
  • 10.5.1. Table Other Technology - by Country
  • 10.5.2. Chart - Other Technology Growth

11. Global Immuno-Oncology Diagnostic Markets - By Customer

• 11.1. Pharma
  • 11.1.1. Table Pharma - by Country
  • 11.1.2. Chart - Pharma Growth
• 11.2. Clinic
  • 11.2.1. Table Clinic - by Country
  • 11.2.2. Chart - Clinic Growth
• 11.3. Other Customer Genetic
  • 11.3.1. Table Other Customer - by Country
  • 11.3.2. Chart - Other Customer Growth

12. Appendices

• 12.1. Prevalence of Cancer Treatments
• 12.2. Growth of Approved IVD Test Menu
• 12.3. Growth of Approved Average IVD Test Fee
• 12.4. The Most Used IVD Assays
• 12.5. The Highest Grossing Assays
• 12.6. Laboratory Fees Schedule

Table of Tables

• Table 1: List of Cancers by Mortality
• Table 2: Overview of Innate and Adaptive Immunity
• Table 3: FDA Approved Monoclonal Antibodies in Cancer treatment
• Table 4: FDA Approved Companion diagnostics in Cancer treatment
• Table 5: Market Players by Type
• Table 6: Five Factors Driving Growth
• Table 7: Three Factors Limiting Growth
• Table 8: Global Market by Region
• Table 9: Global Market by Assay Type
• Table 10: Global Market by Technology
• Table 11: Global Market by Customer
• Table 12: Checkpoint by Country
• Table 13: Cytokine by Country
• Table 14: Germline Genetic by Country
• Table 15: Genetic Tumor by Country
• Table 16: Tumor Microenvironment by Country
• Table 17: Other by Country
• Table 18: NGS by Country
• Table 19: PCR by Country
• Table 20: Fish/IHC by Country
• Table 21: Chem/IA by Country
• Table 22: Other Technology by Country
• Table 23: Pharma by Country
• Table 24: Clinic by Country
• Table 25: Other Customer by Country
• Table 26: The Most Common Assays
• Table 27: Largest Revenue Assays
• Table 28: Clinical Lab Fee Schedule

Table of Figures

• Figure 1: Cancer Death Rates - USA, CDC
• Figure 2: Global healthcare Spending
• Figure 3: The Lab Test Pie
• Figure 4: Helper T Cell Roles
• Figure 5: Antibody Diagram
• Figure 6: Macrophages attack a Cancer Cell
• Figure 7: The Tumour Micro Environment
• Figure 8: The Road to Diagnostics
• Figure 9: Comparing IO Diagnostic and Traditional Testing
• Figure 10: Growth rates of IO DiagnosticTechnologies
• Figure 11: Global Market Density Chart
• Figure 12: Global Market by Assay Type - Base vs. Final
• Figure 13: Global Market by Assay Type Base Year
• Figure 14: Global Market by Assay Type End Year
• Figure 15: Assay Type Share by Year
• Figure 16: Assay Type Segments Growth
• Figure 17: Global Market by Technology - Base vs. Final
• Figure 18: Global Market by Technology Base Year
• Figure 19: Global Market by Technology End Year
• Figure 20: Technology Share by Year
• Figure 21: Technology Segments Growth
• Figure 22: Global Market by Customer - Base vs. Final
• Figure 23: Global Market by Customer Base Year
• Figure 24: Global Market by Customer End Year
• Figure 25: Customer Share by Year
• Figure 26: Customer Segments Growth
• Figure 27: Checkpoint Growth
• Figure 28: Cytokine Growth
• Figure 29: Germline Genetic Growth
• Figure 30: Genetic Tumor Growth
• Figure 31: Tumor Microenvironment Growth
• Figure 32: Other Growth
• Figure 33: NGS Growth
• Figure 34: PCR Growth
• Figure 35: Fish/IHC Growth
• Figure 36: Chem/IA Growth
• Figure 37: Other Technology Growth
• Figure 38: Pharma Growth
• Figure 39: Clinic Growth
• Figure 40: Other Customer Growth
• Figure 41: Prevalence of Cancer Treatments
• Figure 42: IVD Test Menu Growth
• Figure 43: IVD Test Average Fees - A Ten Year View